Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Inari Medical (NASDAQ:NARI) and raises the price target from $55 to $71.
July 31, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Inari Medical and raises the price target from $55 to $71.
The Buy rating and increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100